-
Niagen Bioscience acquires nicotinamide riboside patent portfolio
-
Niagen Bioscience, Inc. (NAGE) Tops Q3 EPS by 3c, offers outlook
-
H.C. Wainwright Reiterates Buy Rating on Niagen Bioscience (NAGE)
-
Niagen Bioscience raises 2025 sales growth outlook to 25%-30%
-
Niagen Bioscience expands IV product to over 900 clinics nationwide
-
Niagen Bioscience (NAGE) PT Raised to $12 at H.C. Wainwright
-
Niagen Bioscience, Inc. (NAGE) Tops Q2 EPS by 2c
-
Niagen Bioscience secures exclusive license for Parkinson's therapy
-
Niagen Bioscience (NAGE) PT Raised to $16 at Canaccord Genuity
-
Niagen Bioscience (NAGE) stock rises following positive clinical study
-
Niagen Bioscience (NAGE) announces positive study on Niagen
-
Niagen Bioscience, Inc. (NAGE) Tops Q1 EPS by 4c
-
Niagen Bioscience (NAGE) announces Niagen IV is available in nearly 600 clinics
-
Niagen Bioscience (NAGE) appoints Dr. Pinchas Cohen to SAB
-
H.C. Wainwright Reiterates Buy Rating on (NAGE)
-
Niagen Bioscience (NAGE) Confirms Its Operations Remain Resilient Amid New Tariff Developments
-
H.C. Wainwright Reiterates Buy Rating on Niagen Bioscience (NAGE)
-
Niagen Bioscience (NAGE) Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
-
ChromaDex (CDXC) rebrands as Niagen Bioscience (NAGE)

